School of Medical Science, Griffith University, Gold Coast, QLD, Australia.
The National Centre for Neuroimmunology and Emerging Diseases, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD Australia.
Asian Pac J Allergy Immunol. 2017 Jun;35(2):75-81. doi: 10.12932/ap0771.
Mast cells (MCs) mediate inflammation through neuropeptides and cytokines, along with histamine and reactive oxygen species (ROS). Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) is an illness characterized by an unexplained disabling fatigue with multiple physiological impairments as well as dysregulated cytokine profiles.
To determine mast cell phenotypes in isolated human PBMCs, in healthy controls and in CFS/ME patients. Second, determine receptor expression of RAGE and its ligand high mobility group box 1 protein (HMGB1).
Moderately severe CFS/ME patients (n=12, mean age 39.25 ± SD3.52 years), severe CFS/ME patients (n=6, mean age 43.00 ± SD4.02 years) and healthy controls (n=13, mean age 42.69 ± SD3.87 years) were included in this study. CFS/ME patients were classified according to the 2011 International Consensus Criteria. LSRFortessa X-20 Flow cytometry was used for the identification of phenotypic peripheral mast cell population in PBMCs using an exclusion marker Lin2 cocktail (anti-CD3, anti-CD14, anti-CD19, anti-CD20 and anti-CD56) and inclusion markers (CD117, CD34, FCεRI, chymase, HLA-DR and CD154) following comparative investigation. HMGB1 and soluble RAGE expression in plasma was measured by sandwich ELISA assay.
There was a significant increase in CD117⁺CD34⁺FCεRI-chymase- mast cell populations in moderate and severe CFS/ME patients compared with healthy controls. There was a significant increase in CD40 ligand and MHC-II receptors on differentiated mast cell populations in the severe CFS/ME compared with healthy controls and moderate CFS/ME. There were no significant differences between groups for HMGB1 and sRAGE.
This preliminary study investigates mast cell phenotypes from PBMCs in healthy controls. We report significant increase of naïve MCs in moderate and severe CFS/ME patients compared with healthy controls. Moreover, a significant increase in CD40 ligand and MHC-II receptors on differentiated mast cells in severe CFS/ME patients. Peripheral MCs may be present in CFS/ME pathology however, further investigation to determine their role is required.
肥大细胞（MCs）通过神经肽和细胞因子，以及组胺和活性氧物质（ROS）介导炎症。慢性疲劳综合征/肌痛性脑脊髓炎（CFS/ME）是一种以无法解释的致残性疲劳为特征的疾病，伴有多种生理损伤以及细胞因子谱失调。
确定健康对照组和 CFS/ME 患者分离的人 PBMCs 中的肥大细胞表型。其次，确定 RAGE 受体及其配体高迁移率族蛋白 1 蛋白（HMGB1）的表达。
纳入 12 例中度严重 CFS/ME 患者（平均年龄 39.25 ± SD3.52 岁）、6 例严重 CFS/ME 患者（平均年龄 43.00 ± SD4.02 岁）和 13 例健康对照者（平均年龄 42.69 ± SD3.87 岁）进行本研究。CFS/ME 患者根据 2011 年国际共识标准进行分类。LSRFortessa X-20 流式细胞仪用于鉴定 PBMC 中外周肥大细胞表型，使用排除标记物 Lin2 鸡尾酒（抗-CD3、抗-CD14、抗-CD19、抗-CD20 和抗-CD56）和包含标记物（CD117、CD34、FCεRI、糜酶、HLA-DR 和 CD154）进行比较研究。通过夹心 ELISA 测定血浆中 HMGB1 和可溶性 RAGE 的表达。
与健康对照组相比，中度和重度 CFS/ME 患者的 CD117+CD34+FCεRI-糜酶-肥大细胞群显著增加。与健康对照组和中度 CFS/ME 相比，重度 CFS/ME 中分化的肥大细胞群上 CD40 配体和 MHC-II 受体显著增加。各组之间 HMGB1 和 sRAGE 无显著差异。
本初步研究调查了健康对照者 PBMC 中的肥大细胞表型。我们报告称，与健康对照组相比，中度和重度 CFS/ME 患者的幼稚 MC 显著增加。此外，重度 CFS/ME 患者分化的肥大细胞上 CD40 配体和 MHC-II 受体显著增加。外周 MC 可能存在于 CFS/ME 病理中，但需要进一步研究以确定其作用。
